Organon (OGN) CMO Juan Camilo Arjona Ferreira Receives Award

What Happened Juan Camilo Arjona Ferreira, Head of R&D & Chief Medical Officer at Organon & Co., had 11,519 restricted stock units convert to 11,519 shares on August 11, 2026 (reported as derivative exercise/conversion). To satisfy tax withholding, 4,134 of those shares were withheld/disposed at $13.62 per share, totaling $56,305. The conversion entries are reported at $0.00 per share because these were RSU settlements rather than purchases.

Key Details

• Transaction date: August 11, 2026; Form filed August 12, 2026 (timely).
• Acquired: 11,519 shares via RSU conversion (reported as code M).
• Disposed/Withheld for taxes: 4,134 shares at $13.62 each = $56,305 (reported as code F).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F1—each RSU equals the right to one share; F2—these RSUs vested in three equal installments with the final vesting on August 11, 2026.
• No indication of a 10b5-1 plan or late filing in this report.

Context This was a routine RSU vesting and tax-withholding event, not an open-market purchase or a voluntary sale. The 4,134-share disposition reflects shares withheld to cover tax obligations (common for equity compensation), not an express bearish trade signal.